Histogenics Corp. (HSGX) Stock Price Up 11.9%
Histogenics Corp. (NASDAQ:HSGX) rose 11.9% during mid-day trading on Monday . The company traded as high as $2.17 and last traded at $2.07, with a volume of 119,552 shares trading hands. The stock had previously closed at $1.85.
HSGX has been the topic of a number of recent research reports. BTIG Research restated a “neutral” rating on shares of Histogenics Corp. in a research report on Sunday, March 13th. Canaccord Genuity reiterated a “buy” rating on shares of Histogenics Corp. in a report on Thursday, May 12th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $12.13.
The firm’s market cap is $26.67 million. The firm has a 50 day moving average of $1.85 and a 200 day moving average of $2.35.
Histogenics Corp. (NASDAQ:HSGX) last posted its quarterly earnings data on Thursday, May 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by $0.01. During the same period in the prior year, the business posted ($0.60) earnings per share. Analysts anticipate that Histogenics Corp. will post ($2.15) EPS for the current year.
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.